GB2234896A — Delayed release formulations
Assigned to Sandoz AG · Expires 1991-02-20 · 35y expired
What this patent protects
A sustained release formulation of a peptide drug compound, preferably a somatostatin like octreotide, e.g. as a pamoate salt. The drug compound is present in a polymeric carrier, preferably a polylactide-co-glycolide especially a poly(lactide-co-glycolide)glucose. The formulatio…
USPTO Abstract
A sustained release formulation of a peptide drug compound, preferably a somatostatin like octreotide, e.g. as a pamoate salt. The drug compound is present in a polymeric carrier, preferably a polylactide-co-glycolide especially a poly(lactide-co-glycolide)glucose. The formulation is preferably a depot formulation in the form of a monolithic microparticle.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.